PUBLIC COMPANY
saveDizal Pharmaceutical Co Ltd
updated 2mo ago
community read0 votes
pipeline
3
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
2Phase 21Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
- phase1DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- phase3A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- phase2Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
- phase2DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
- phase1A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)
- phase1A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
- phase3A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
🐶 Hiring Signal
News
- STAT+: Akero team, backed by Fairmount, launches new immunology companyFDA approves injectable Leqembi, another post-Makary reversal, and other biotech news from The Readoutstat · 1mo ago
comments(0)
5-min edit window · permanent after that